{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:01:19Z","timestamp":1787029279381,"version":"build-2736575974"},"reference-count":60,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T00:00:00Z","timestamp":1680566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Kurt R. Zinn"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>A paradigm shift is underway in cancer diagnosis and therapy using radioactivity-based agents called radiopharmaceuticals. In the new strategy, diagnostic imaging measures the tumor uptake of radioactive agent \u201cX\u201d in a patient\u2019s specific cancer, and if uptake metrics are realized, the patient can be selected for therapy with radioactive agent \u201cY\u201d. The X and Y represent different radioisotopes that are optimized for each application. X\u2013Y pairs are known as radiotheranostics, with the currently approved route of therapy being intravenous administration. The field is now evaluating the potential of intra-arterial dosing of radiotheranostics. In this manner, a higher initial concentration can be achieved at the cancer site, which could potentially enhance tumor-to-background targeting and lead to improved imaging and therapy. Numerous clinical trials are underway to evaluate these new therapeutic approaches that can be performed via interventional radiology. Of further interest is changing the therapeutic radioisotope that provides radiation therapy by \u03b2- emission to radioisotopes that also decay by \u03b1-particle emissions. Alpha (\u03b1)-particle emissions provide high energy transfer to the tumors and have distinct advantages. This review discusses the current landscape of intra-arterially delivered radiopharmaceuticals and the future of \u03b1-particle therapy with short-lived radioisotopes.<\/jats:p>","DOI":"10.3390\/pharmaceutics15041138","type":"journal-article","created":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T02:03:00Z","timestamp":1680573780000},"page":"1138","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Intra-Arterial Delivery of Radiopharmaceuticals in Oncology: Current Trends and the Future of Alpha-Particle Therapeutics"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9754-8261","authenticated-orcid":false,"given":"Nathan","family":"Kauffman","sequence":"first","affiliation":[{"name":"Comparative Medicine and Integrative Biology, Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, MI 48824, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Morrison","sequence":"additional","affiliation":[{"name":"Advanced Radiology Services, 3264 N Evergreen Dr, Grand Rapids, MI 49525, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"O\u2019Brien","sequence":"additional","affiliation":[{"name":"Department of Radiology, Henry Ford Health System, Detroit, MI 48202, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3098-3397","authenticated-orcid":false,"given":"Jinda","family":"Fan","sequence":"additional","affiliation":[{"name":"Departments of Radiology and Chemistry, Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, MI 48824, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt R.","family":"Zinn","sequence":"additional","affiliation":[{"name":"Departments of Radiology, Biomedical Engineering, Small Animal Clinical Sciences, Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, MI 48824, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"193","DOI":"10.7150\/ijms.3635","article-title":"Cancer and radiation therapy: Current advances and future directions","volume":"9","author":"Baskar","year":"2012","journal-title":"Int. J. Med. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.2478\/raon-2019-0006","article-title":"A current review of dose-escalated radiotherapy in locally advanced non-small cell lung cancer","volume":"53","author":"Ma","year":"2019","journal-title":"Radiol. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1007\/s00520-018-4474-9","article-title":"A review of the Rapid Response Radiotherapy Program in patients with advanced cancer referred for palliative radiotherapy over two decades","volume":"27","author":"Razvi","year":"2019","journal-title":"Support. Care Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3322\/caac.21578","article-title":"Brachytherapy: An overview for clinicians","volume":"69","author":"Chargari","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.21037\/jgo.2017.09.10","article-title":"Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: Expert consensus","volume":"8","author":"Kennedy","year":"2017","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3322\/canjclin.50.6.380","article-title":"Modern prostate brachytherapy","volume":"50","author":"Ragde","year":"2000","journal-title":"CA Cancer J. Clin."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.2967\/jnumed.117.189944","article-title":"Pretargeted Imaging and Therapy","volume":"58","author":"Altai","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00259-002-1090-0","article-title":"Radioimmunotherapy: Is avidin-biotin pretargeting the preferred choice among pretargeting methods?","volume":"30","author":"Paganelli","year":"2003","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Pastorino, S., Baldassari, S., Ailuno, G., Zuccari, G., Drava, G., Petretto, A., Cossu, V., Marini, C., Alfei, S., and Florio, T. (2021). Two Novel PET Radiopharmaceuticals for Endothelial Vascular Cell Adhesion Molecule-1 (VCAM-1) Targeting. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13071025"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Verhoeven, M., Seimbille, Y., and Dalm, S.U. (2019). Therapeutic Applications of Pretargeting. Pharmaceutics, 11.","DOI":"10.3390\/pharmaceutics11090434"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1021\/acs.bioconjchem.9b00761","article-title":"Antibody Pretargeting Based on Bioorthogonal Click Chemistry for Cancer Imaging and Targeted Radionuclide Therapy","volume":"31","author":"Rondon","year":"2020","journal-title":"Bioconjugate Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1039\/D2MD00360K","article-title":"Pretargeted imaging beyond the blood\u2014Brain barrier","volume":"14","author":"Shalgunov","year":"2023","journal-title":"RSC Med. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1210\/jcem.86.4.7407","article-title":"Current Approaches to Primary Therapy for Papillary and Follicular Thyroid Cancer","volume":"86","author":"Mazzaferri","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.clon.2017.02.009","article-title":"Targeted Therapy in Thyroid Cancer: State of the Art","volume":"29","author":"Valerio","year":"2017","journal-title":"Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1021\/bc200151q","article-title":"Theranostics: Combining imaging and therapy","volume":"22","author":"Kelkar","year":"2011","journal-title":"Bioconjugate Chem."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Aboagye, E.O., Barwick, T.D., and Haberkorn, U. (2023). Radiotheranostics in oncology: Making precision medicine possible. CA Cancer J. Clin.","DOI":"10.3322\/caac.21768"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Hennrich, U., and Kopka, K. (2019). Lutathera((R)): The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy. Pharmaceuticals, 12.","DOI":"10.3390\/ph12030114"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2967\/jnumed.122.264104","article-title":"The Prognostic Value of Posttreatment (68)Ga-PSMA-11 PET\/CT and (18)F-FDG PET\/CT in Metastatic Castration-Resistant Prostate Cancer Treated with (177)Lu-PSMA-617 and NOX66 in a Phase I\/II Trial (LuPIN)","volume":"64","author":"Pathmanandavel","year":"2023","journal-title":"J. Nucl. Med."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Zhang, H., Koumna, S., Pouliot, F., Beauregard, J.M., and Kolinsky, M. (2021). PSMA Theranostics: Current Landscape and Future Outlook. Cancers, 13.","DOI":"10.3390\/cancers13164023"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.2967\/jnumed.115.171397","article-title":"PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617","volume":"57","author":"Kratochwil","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","article-title":"Radiopharmaceutical therapy in cancer: Clinical advances and challenges","volume":"19","author":"Sgouros","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Ailuno, G., Iacobazzi, R.M., Lopalco, A., Baldassari, S., Arduino, I., Azzariti, A., Pastorino, S., Caviglioli, G., and Denora, N. (2021). The Pharmaceutical Technology Approach on Imaging Innovations from Italian Research. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13081214"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Bolzati, C., and Dolmella, A. (2019). Nitrido Technetium-99 m Core in Radiopharmaceutical Applications: Four Decades of Research. Inorganics, 8.","DOI":"10.3390\/inorganics8010003"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"12913","DOI":"10.3390\/molecules200712913","article-title":"68Ga-Based radiopharmaceuticals: Production and application relationship","volume":"20","author":"Velikyan","year":"2015","journal-title":"Molecules"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.3389\/fonc.2020.01443","article-title":"Strategies for Improved Intra-arterial Treatments Targeting Brain Tumors: A Systematic Review","volume":"10","author":"Huang","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/00004424-200105000-00001","article-title":"Local intra-arterial drug delivery for prevention of restenosis: Comparison of the efficiency of delivery of different radiopharmaceuticals through a porous catheter","volume":"36","author":"Tepe","year":"2001","journal-title":"Investig. Radiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3389\/fphar.2019.00450","article-title":"Theranostics in Interventional Oncology: Versatile Carriers for Diagnosis and Targeted Image-Guided Minimally Invasive Procedures","volume":"10","author":"Degrauwe","year":"2019","journal-title":"Front. Pharm."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1053\/j.semnuclmed.2016.01.008","article-title":"Intra-Arterial Radionuclide Therapies for Liver Tumors","volume":"46","author":"Bozkurt","year":"2016","journal-title":"Semin. Nucl. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1023\/A:1013569329846","article-title":"Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer","volume":"12","author":"Gray","year":"2001","journal-title":"Ann. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s12325-016-0324-7","article-title":"Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma","volume":"33","author":"Kallini","year":"2016","journal-title":"Adv. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Facciorusso, A., Bargellini, I., Cela, M., Cincione, I., and Sacco, R. (2020). Comparison between Y90 Radioembolization Plus Sorafenib and Y90 Radioembolization alone in the Treatment of Hepatocellular Carcinoma: A Propensity Score Analysis. Cancers, 12.","DOI":"10.3390\/cancers12040897"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1148\/radiol.2018171768","article-title":"Radiation Segmentectomy: Potential Curative Therapy for Early Hepatocellular Carcinoma","volume":"287","author":"Lewandowski","year":"2018","journal-title":"Radiology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jhep.2013.06.015","article-title":"Radiation lobectomy: Time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection","volume":"59","author":"Vouche","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jvir.2019.05.023","article-title":"Safety of Combined Yttrium-90 Radioembolization and Immune Checkpoint Inhibitor Immunotherapy for Hepatocellular Carcinoma","volume":"31","author":"Zhan","year":"2020","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1103\u20131112.e1112","DOI":"10.1016\/j.jvir.2021.01.282","article-title":"Yttrium-90 Radioembolization to the Prostate Gland: Proof of Concept in a Canine Model and Clinical Translation","volume":"32","author":"Mouli","year":"2021","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_36","first-page":"761","article-title":"Efficacy of intraarterial chemoinfusion therapy for locally advanced breast cancer patients: A retrospective analysis of 28 cases","volume":"6","author":"Zhang","year":"2013","journal-title":"OncoTargets Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s41181-019-0066-3","article-title":"The various therapeutic applications of the medical isotope holmium-166: A narrative review","volume":"4","author":"Klaassen","year":"2019","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s13566-017-0315-6","article-title":"Intratumoral treatment with radioactive beta-emitting microparticles: A systematic review","volume":"6","author":"Bakker","year":"2017","journal-title":"J. Radiat. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s40336-016-0220-9","article-title":"Intra-arterial radiopeptide therapy of hepatic metastases of neuroendocrine tumors: A systematic review","volume":"5","author":"Feuerecker","year":"2017","journal-title":"Clin. Transl. Imaging"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1158\/1078-0432.CCR-10-0004","article-title":"Intraindividual comparison of selective arterial versus venous 68Ga-DOTATOC PET\/CT in patients with gastroenteropancreatic neuroendocrine tumors","volume":"16","author":"Kratochwil","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1530\/ERC-11-0144","article-title":"Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases","volume":"18","author":"Kratochwil","year":"2011","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"20210403","DOI":"10.1259\/bjr.20210403","article-title":"Dosimetric analyses of intra-arterial versus standard intravenous administration of 177Lu-DOTATATE in patients of well differentiated neuroendocrine tumor with liver-dominant metastatic disease","volume":"94","author":"Thakral","year":"2021","journal-title":"Br. J. Radiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jvir.2021.10.016","article-title":"Selective Intra-Arterial Lutetium-177-Labeled Prostate-Specific Membrane Antigen Therapy for Castration-Resistant Prostate Cancer: Initial Results","volume":"33","author":"Sayman","year":"2022","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1055\/a-0802-5039","article-title":"Intraindividual comparison of selective intraarterial versus systemic intravenous 68Ga-DOTATATE PET\/CT in patients with inoperable meningioma","volume":"58","author":"Verburg","year":"2019","journal-title":"Nuklearmedizin"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"406","DOI":"10.2967\/jnumed.121.262491","article-title":"Intraarterial Administration Boosts (177)Lu-HA-DOTATATE Accumulation in Salvage Meningioma Patients","volume":"63","author":"Vonken","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13063-019-3888-0","article-title":"Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: Study protocol for a multicenter, randomized controlled trial (LUTIA trial)","volume":"21","author":"Ebbers","year":"2020","journal-title":"Trials"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1007\/s00259-011-1902-1","article-title":"Peptide receptor radionuclide therapy with (1)(7)(7)Lu-DOTATATE: The IEO phase I-II study","volume":"38","author":"Bodei","year":"2011","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Tafreshi, N.K., Doligalski, M.L., Tichacek, C.J., Pandya, D.N., Budzevich, M.M., El-Haddad, G., Khushalani, N.I., Moros, E.G., McLaughlin, M.L., and Wadas, T.J. (2019). Development of Targeted Alpha Particle Therapy for Solid Tumors. Molecules, 24.","DOI":"10.3390\/molecules24234314"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","article-title":"225Ac-PSMA-617 for PSMA-Targeted alpha-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer","volume":"57","author":"Kratochwil","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.2967\/jnumed.121.263230","article-title":"Targeted alpha-Emitter Therapy with (212)Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Humans Dose-Escalation Clinical Trial","volume":"63","author":"Delpassand","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1034315","DOI":"10.3389\/fmed.2022.1034315","article-title":"Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists","volume":"9","author":"Shi","year":"2022","journal-title":"Front. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2967\/jnumed.108.058651","article-title":"MIRD Pamphlet No. 22 (abridged): Radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy","volume":"51","author":"Sgouros","year":"2010","journal-title":"J. Nucl. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2147\/HP.S93413","article-title":"The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy","volume":"3","author":"Muz","year":"2015","journal-title":"Hypoxia"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2967\/jnumed.122.264805","article-title":"The Future of Targeted alpha-Therapy Is Bright, but Rigorous Studies Are Necessary to Advance the Field","volume":"64","author":"Strosberg","year":"2023","journal-title":"J. Nucl. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1007\/s00259-014-2857-9","article-title":"(2)(1)(3)Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: A first-in-human experience","volume":"41","author":"Kratochwil","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/COC.0000000000000353","article-title":"Safety and Outcome Measures of First-in-Human Intraperitoneal alpha Radioimmunotherapy with 212Pb-TCMC-Trastuzumab","volume":"41","author":"Meredith","year":"2018","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1007\/s00259-018-4003-6","article-title":"Treatment of carcinoma in situ of the urinary bladder with an alpha-emitter immunoconjugate targeting the epidermal growth factor receptor: A pilot study","volume":"45","author":"Autenrieth","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"15618","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Alard","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Aicher, A., Sindrilaru, A., Crisan, D., Thaiss, W., Steinacker, J., Beer, M., Wiegel, T., Scharffetter-Kochanek, K., Beer, A.J., and Prasad, V. (2022). Short-Interval, Low-Dose Peptide Receptor Radionuclide Therapy in Combination with PD-1 Checkpoint Immunotherapy Induces Remission in Immunocompromised Patients with Metastatic Merkel Cell Carcinoma. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14071466"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.ijrobp.2021.10.013","article-title":"Targeted Alpha Particle Therapy Remodels the Tumor Microenvironment and Improves Efficacy of Immunotherapy","volume":"112","author":"Perrin","year":"2022","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/4\/1138\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:09:33Z","timestamp":1760123373000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/4\/1138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,4]]},"references-count":60,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["pharmaceutics15041138"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics15041138","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,4]]}}}